📌 Key Takeaways
- Topic: Silica Thermal Expansion Coefficient: CTE Values for Quartz vs Fused Silica
- Keywords: silica anti settling agent
- Published: 2026-11-20 13:06:40
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silica Glidant for Tablets: How It Improves Powder Flow and Typical Dosages
- Silica as a Thickening Agent: How It Works in Liquids, Resins and Gels
- Li, X. et al. An RGD-modified hollow silica@ Au core/shell nanoplatform for tumor combination therapy. Acta Biomater. 62, 273-283 (2017). Piece CAS PubMed Google Scholar
- Spherical Silica Manufacturer: Key Capabilities, Purity Control and Selection Criteria
- Silica for Paint: Matting, Anti-Settling and Rheology Functions Explained
- Silica as an Anti-Settling Agent: How It Keeps Pigments and Fillers Suspended
Wood Coating Matting Agent: How to Achieve a Low-Gloss, Clear Finish
What is silica (SiO₂)?
silicon oxide anode The unique properties of MSNs make it greatly superior for the construction of multifunctional nanocomposites and drug delivery system. Different therapeutic nanoplatforms obtained through the careful design of MSNs have revealed promising potential in the field of targeted disease therapy. Current applications of MSNs include tumor therapy, 367, 368, 369 anti-infection therapy (bacteria and virus), 370, 371, 372, 373 anti-oxidant/anti-inflammatory therapy (Alzheimer's disease, acute kidney injury, etc.), 374, 375, 376 and metabolic diseases treatment (diabetes, osteoporosis, fatty liver, etc) 377, 378, 379, 380 (Fig. 7 ). In general, the targeted therapeutic characteristics of MSNs can be reflected in the following aspects: (1) Loading chemotherapy drugs or other drugs with toxic side influences, so that they can be released in a controlled manner by MSNs at the targeted sites to prevent their premature release. (2) Selective enrichment at the lesion sites through passive targeting or active targeting, resulting in the higher therapeutic efficacy. (3) Use the MSNs matrix to develop a non-invasive, spatial and temporal controllable targeted therapeutic plan, consequently to overcome the limitations and defects of conventional clinical treatment modalities. To date, the emerging targeted therapeutic modalities developed based on MSNs include dynamic therapy such as photodynamic, sonodynamic and chemodynamic therapies, thermal ablation therapy such as photothermal therapy and magnetic thermotherapy, enzyme-like catalytic therapy, immunotherapy, gene therapy, and others. Meanwhile, the integration of various therapeutic modalities on a single MSNs is expected to enhance the therapeutic efficacy synergistically (Fig. 7 ). In this part, we will discuss MSNs-based therapeutic modalities.
What is the difference between fumed silica and precipitated silica?
silica quote Bagshaw, S. A., Prouzet, E. & Pinnavaia, T. J. Templating of mesoporous molecular sieves by nonionic polyethylene oxide surfactants. Science 269, 1242-1244 (1995). Article PubMed Google Scholar
What drives silica raw material prices?
silica market trends MSNs-based scaffolds can enhance the cell proliferation, migration, adhesion and differentiation in bone tissue engineering. Many studies have systematically investigated and revealed the function of MSNs-based scaffolds in the regulation of cellular functions. 483, 484, 485, 486 Bone defects-involved regenerative mend is challenging to obtain a desired outcome due to the delay of early vascularization and poor osteogenic activity of bone implants. In this regard, researchers have designed a polycaprolactone network containing vascular-like structure, and introduced a nanofibrous gelatin-silica scaffold into it. Dimethyloxalylglycine (DMOG) and peptide-1 (BFP) were then loaded into MSNs, and the differential spatial distribution and sequential release of DMOG and BFP allowed the bioactive scaffold to promote angiogenesis by stimulating the migration of human umbilical vein endothelial cells (HUVECs), the tube formation and the expression of angiogenesis-related genes/proteins (HIF-1α, e-NOS, KDR and VEGF), as well as enhance osteogenesis by upregulating the expression of bone marrow-derived mesenchymal stem cells (BMSCs)-related osteogenic genes (Runx2, Col I, OPN and OCN) and promoting mineral matrix formation. 487 Apart from, Mora-Raimundo et al. reported MSNs as a nanocarrier to deliver SOST small interfering RNA (siRNA) and osteostatin, and the as-designed system could be used for osteoporosis remission via enhancing the bone microarchitecture. 379 Wang et al. designed a biomimetic silica-collagen scaffold via a robust biosilicification tactic, and the silica-collagen scaffold could mimic the distinctive microenvironment of bone extracellular matrix (ECM), resulting in the improvement of mesenchymal stem cell (MSC) recruitment and bone repair. 488 These MSNs-based scaffolds have excellent potential for clinical translation in the treatment of bone defects.
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.